*Today 2PM ET* Fireside Chat with ARTV CEO: In Case You Missed Allo-NK rRA Data

Research evidence excerpt

*Today 2PM ET* Fireside Chat with ARTV CEO: In Case You Missed Allo-NK rRA Data

USA | Biotechnology

Artiva Biotherapeutics EquityMayResearch11, 2026

FLASH NOTE*Today 2PM ET* Fireside Chat with ARTV CEO:

RATING BUYIn Case You Missed Allo-NK rRA Data

PRICE $10.89^

*Today* Monday, May 11th, at 2PM ET, we are hosting a virtual fireside chat/

webinar with ARTV CEO (Fred Aslan), following recent RA efficacy data (Topline, PRICE TARGET | % TO PT $23.00 | +111%

Catch-up). Key topics will include key highlights from RA data, pivotal alignment 52W HIGH-LOW $14.53 - $1.47

and RCT design/ expectations, refractory RA treatment paradigm, competitive FLOAT (%) | ADV MM (USD) 49.1% | 5.17

landscape and commercial opportunity, and AlloNK opportunity beyond RA in MARKET CAP $265.7M

other autoimmune indications. Email us with questions of interest. TICKER ARTV ^Prior trading day's closing price unless otherwise

noted.

Date: Monday, May 11th, 2026

Time: 2:00pm ET / 11:00am PT

Please REGISTER HERE for this event. Replay details to be shared post-call. Please reach out if

interested.

Speaker: Fred Aslan, MD, CEO of Artiva Therapeutics

Host: Roger Song, MD, CFA, Senior Analyst

Please email any questions of interest to Roger Song at rsong@jefferies.com, before or during the fireside

chat.

Key discussion topics:

Highlights of the RA efficacy data•

baseline •

ACR50/mACR50 •

durability •

safety •

Pivotal alignment and RCT design/ timing/ expectation.•

Refractory RA current treatment paradigm.•

Competitive landscape in refractory RA.•

Commercial opportunity in refractory RA.•

AlloNK opportunity beyond RA in other autoimmune indications (SjD, SSc)•

Artiva is a clinical-stage biotechnology company whose mission is to develop effective, safe Roger Song, MD, CFA * | Equity Analyst